Immunitybio, Inc.

This program offers a modified version of the BCG vaccine (rMBCG) to people with non-muscle invasive bladder cancer who cannot join a clinical trial. The treatment is given directly into the bladder to help control the cancer. It is for patients who would normally receive standar…

This expanded access program provides nogapendekin-alfa inbakicept (NAI) to adults with solid tumors who have low lymphocyte counts caused by prior cancer treatments like chemotherapy, immunotherapy, or radiation. The goal is to reverse and maintain healthy lymphocyte levels. It …

This early-phase study tests a new type of immune cell therapy (CD19 t-haNK) alone or with two other drugs (N-803 and rituximab) in up to 20 adults with relapsed or refractory non-Hodgkin lymphoma. The main goal is to check safety, and researchers will also see if the treatment s…

This early-stage trial is testing a new treatment called CD19 t-haNK, which uses specially engineered natural killer cells to target and attack cancer cells. It is being studied alone and in combination with the drug rituximab for people with relapsed or refractory B-cell non-Hod…

This study tests a modified version of the BCG vaccine (rMBCG) given directly into the bladder for people with non-muscle invasive bladder cancer (NMIBC). The goal is to see if it is safe and can control the cancer. About 40 adults who have not had BCG before will take part. The …

This study tests a combination of drugs (nogapendekin alfa inbakicept, PD-L1 t-haNK, and bevacizumab) with or without tumor treatment fields in people whose glioblastoma has returned or worsened. The goal is to see if these treatments can safely control the cancer and improve sur…

This study tests a drug called Anktiva (NAI) in 40 adults with Long COVID—symptoms that stick around after a COVID infection clears. The main goal is to see if the drug is safe, and researchers will also check if it helps reduce symptoms. Participants must be between 18 and 70 an…

This phase 3 trial tests whether adding an experimental drug (N-803) to standard chemotherapy (docetaxel) can help people with advanced non-small cell lung cancer whose disease has stopped responding to immunotherapy. About 507 participants will be randomly assigned to receive ei…

This study tests a new combination of drugs (CD19 t-haNK, N-803, and rituximab) in 20 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors and improve survival. Particip…

This early-phase trial tests a new treatment called CD19 t-hANK for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back after previous treatments. The therapy uses specially designed immune cells to attack cancer cells. Up to 10 participant…

This study tests a new treatment for people with a tough-to-treat type of ovarian cancer that no longer responds to platinum-based chemotherapy. The treatment uses a person's own immune cells (called natural killer cells) that are boosted in a lab and given back along with a drug…

This Phase 2 trial is testing the safety of a drug called Anktiva (N-803) in 20 adults with Long COVID. Participants receive up to two doses and are monitored for side effects and changes in symptoms. The goal is to see if this immune-boosting drug is safe enough to study further…